Is it safe to take live vaccines post cosentyx?

Is it safe to take live vaccines after Cosentyx?

Cosentyx (secukinumab) weakens immune function by blocking interleukin-17A, so live vaccines carry elevated infection risk for patients taking the drug. Current guidelines advise against live vaccines during Cosentyx treatment and for at least 6 months after stopping.

Why do guidelines recommend waiting 6 months?

Secukinumab has a half-life of 25-30 days. It takes roughly five half-lives to reach sub-therapeutic levels. That estimate combined with clinical trial safety data leads regulators and manufacturers to recommend a 6-month washout period before live vaccines.

What happens if you get a live vaccine too early?

Patients who receive live vaccines while on Cosentyx or shortly after may develop disseminated infections. Case reports document varicella and measles complications in immunosuppressed individuals. Cosentyx’s prescribing information explicitly lists live vaccines as contraindicated.

Can biosimilars or other IL-17 inhibitors raise the same issues?

Secukinumab and other IL-17 blockers (brodalumab, ixekizumab) share the same warnings. Biosimilars to secukinumab, once approved, will inherit the same vaccine guidelines. No evidence yet shows any difference in vaccine risk profiles.

When does Cosentyx patent expire?

Cosentyx patents expire in 2031 in the US, allowing potential biosimilar entry after that date.